Lotus Therapeutics Appoints Leslie Felix as Chief Growth Officer

Industry veteran to drive strategic expansion and innovation in complex generics

BOCA RATON, Fla., June 4, 2025 /PRNewswire/ -- Lotus Therapeutics, the generic division of Speranza Therapeutics, proudly announces the appointment of Leslie Felix as Chief Growth Officer. With over 25 years of executive experience in the pharmaceutical sector, Felix brings a proven track record in the generics market, poised to steer Lotus Therapeutics through its next phase of growth and innovation.

Established in 2024, Lotus Therapeutics is committed to revolutionizing access to life-changing medications by focusing on the development of complex and unique generic formulations. The company's mission centers on addressing unmet medical needs through innovative therapies, ensuring that advancements are accessible to those who need them most.

Felix has successfully led P&L operations exceeding $300 million and has held key senior positions at leading pharmaceutical companies, where his go-to-market strategies solidified their leadership in the generics space. In 2020, he founded the Authorized Generics Coalition, reinforcing his dedication to industry advancement and patient access.

"Leslie's depth of expertise and forward-thinking approach are exactly what Lotus Therapeutics needs as we enter a pivotal phase of expansion," said Sal Rafanelli, CEO of Lotus Therapeutics. "We are excited to welcome him to our leadership team and look forward to the impact he will make in driving our strategic growth initiatives."

As Chief Growth Officer, Felix will oversee strategic partnerships and market development efforts, positioning Lotus Therapeutics for long-term success. His leadership is expected to enhance the company's capabilities in managing post-Loss of Exclusivity (LOE) assets and expanding its portfolio of complex generics.

Lotus Therapeutics' foundation is built upon a legacy of innovation, with its executive team having previously founded BioMatrix®, a leader in specialty infusion services, and Speranza Therapeutics, known for launching ST Genesis®. This heritage underscores the company's commitment to delivering affordable, high-quality therapies that make a meaningful impact on patient lives

For more information about Lotus Therapeutics and its mission to transform patient care with innovative generics, visit https://lotusthera.com.

Media Contact: Lauren Saccone, lsaccone@speranzatherapeutics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lotus-therapeutics-appoints-leslie-felix-as-chief-growth-officer-302473423.html

SOURCE Speranza Therapeutics